Immunic’s Promising Market Potential: Buy Rating Backed by Vidofludimus Calcium’s Efficacy, Safety, and Strategic Financial Path

William Blair analyst Myles Minter has reiterated their bullish stance on IMUX stock, giving a Buy rating on November 7.Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow. Myles Minter has given his Buy rating due to a combination of factors that highlight Immunic’s potential in the market. Vidofludimus calcium (vido) has shown promising disease-modifying activity in patients with challenging conditions, particularly those with limited active lesions, as evidenced by the Phase IIb CALLIPER study. Minter believes that vido’s safety and efficacy as an oral therapy make it a strong competitor against existing treatments like anti-CD20 injectables and emerging BTK inhibitors. Additionally, vido’s differentiation from other DHODH inhibitors, such as Aubagio, due to its lower liver safety risks and unique mechanism involving Nurr1 activation, further supports its potential market share.Minter also points to the financial strategy and clinical trial progress as key reasons for the Buy rating. Despite existing financial challenges, there is a clear funding path through the PIPE/2025 public offering structure to support the ENSURE-1 and -2 trials in relapsing MS, with data expected by the end of 2026. These trials are anticipated to yield positive results, given the precedent set by similar treatments and the absence of liver safety concerns. Furthermore, the recent acceptance of a patent application extending protection for vido in MS until 2041 strengthens Immunic’s position in the market, providing a long-term competitive advantage. According to TipRanks, Minter is a 5-star analyst with an average return of 29.1% and a 59.85% success rate. Minter covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Larimar Therapeutics, and Arcturus Therapeutics. In another report released on November 7, Roth MKM also initiated coverage with a Buy rating on the stock with a $3.00 price target.